Idéal Investisseur
Français English
CAC 40 : Market closed
8 218,24 pts
-0.32%


Last updated : 05/06/2026 - 17h29
🏠 Home   ➤    Stock news

DBV Technologies Shares Drop Nearly 4% Breaking Below 200-Day Moving Average

The French biotech company experiences another session of decline, while the Paris market also closes in negative territory. The stock continues its slide that started several weeks ago, now trading below all its moving averages. The price dynamics contrast with its largely positive annual trajectory.


DBV Technologies Shares Drop Nearly 4% Breaking Below 200-Day Moving Average

The stock breaks its support at €3.01 and moves away from all its moving averages

DBV Technologies stock fell by 4.19% to €2.88 at close, while the SBF 120 only dropped 0.27%. The stock has broken through its support level identified at €3.01, which had previously contained declines in recent sessions.

The biotech is now trading below its three moving averages: 11.9% below the MM20 (€3.27) and 16% below the MM50 (€3.43). The price has also fallen below the MM200 at €2.97, a medium-term benchmark that had until now acted as a floor.

The RSI at 36 indicates the exhaustion of sellers over the past few weeks without yet entering an oversold zone. Over three months, the decline reaches 23.3%, while the performance over one year remains positive at 106%.

A decline that persists despite the expansion of the Viaskin program to infants

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

Today's movement extends a downward trend already documented this week, following the breach of a technical threshold at the beginning of the month. On Tuesday, the stock had already declined on the eve of the mixed general meeting held on June 3.

In clinical developments, DBV Technologies announced earlier this week the screening of the first participant in the phase 2 THRIVE study, which assesses the Viaskin Peanut patch in infants aged 6 to 12 months allergic to peanuts. The expansion of the program to this very young population has not been enough to stop the trend.

The session takes place in a less favorable Parisian context, with the CAC 40 down by 0.26% and the Nasdaq dropping 1.58% during trading in the United States. In the short term, the most immediate technical marker to observe is the crossing below the MM200 at €2.97.



Sector Santé · Biotechnologies · Vaccins et laboratoires de recherche Biotechnologie


Assurance vie

Context

Period
  • Period: 1T2026
Key reported figures
  • Revenue: 1M€dedollars
  • Net income: -47,6M€dedollars
  • Free cash flow: -49M€dedollars
Guidance from the release
  • Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
  • Augmentation significative des dépenses de R&D.
  • Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
  • Dépôt de la demande de licence biologique prévu pour 2026.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit